Literature DB >> 18385987

Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin.

E E M Brouwers1, M M Tibben, D Pluim, H Rosing, H Boot, A Cats, J H M Schellens, J H Beijnen.   

Abstract

We present a highly sensitive method for the determination of platinum (Pt) in DNA extracts of peripheral blood mononuclear cells (PBMCs) and tissue samples from patients treated with cisplatin. The method is based on the measurement of Pt by inductively coupled plasma mass spectrometry (ICP-MS) and allows quantification of Pt-DNA adducts in PBMCs isolated from 10 mL blood and 1 mg tissue. The lower limit of quantification is 0.75 pg Pt or 7.5 fg Pt μg(-1) DNA when using 100 μg DNA. The method proved to be accurate and precise. The results obtained using the ICP-MS method were in good agreement with results from the alternative (32)P-postlabelling assay. The ICP-MS method was, however, more sensitive and proved to be less laborious. The advantages of the presented ICP-MS technique were demonstrated by the analysis of PBMCs, normal gastric tissue, and gastric tumour tissue of patients treated with cisplatin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18385987     DOI: 10.1007/s00216-008-2034-8

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  16 in total

1.  Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines.

Authors:  Ti Zhang; Shuang Cai; Chad Groer; Wai Chee Forrest; Qiuhong Yang; Eva Mohr; Justin Douglas; Daniel Aires; Sandra M Axiak-Bechtel; Kimberly A Selting; Jeffrey A Swarz; Deborah J Tate; Jeffrey N Bryan; M Laird Forrest
Journal:  J Pharm Sci       Date:  2016-05-04       Impact factor: 3.534

2.  Phase I-II clinical trial of hyaluronan-cisplatin nanoconjugate in dogs with naturally occurring malignant tumors.

Authors:  Shuang Cai; Ti Zhang; W C Forrest; Qiuhong Yang; Chad Groer; Eva Mohr; Daniel J Aires; Sandra M Axiak-Bechtel; Brian K Flesner; Carolyn J Henry; Kimberly A Selting; Deborah Tate; Jeffrey A Swarz; Jeffrey N Bryan; M Laird Forrest
Journal:  Am J Vet Res       Date:  2016-09       Impact factor: 1.156

3.  Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles.

Authors:  Xiang-Hong Peng; Yiqing Wang; Donghai Huang; Yuxiang Wang; Hyung Juc Shin; Zhengjia Chen; Michael B Spewak; Hui Mao; Xu Wang; Ying Wang; Zhuo Georgia Chen; Shuming Nie; Dong M Shin
Journal:  ACS Nano       Date:  2011-11-04       Impact factor: 15.881

4.  Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer.

Authors:  Mette Sprauten; Thomas H Darrah; Derick R Peterson; M Ellen Campbell; Robyn E Hannigan; Milada Cvancarova; Clair Beard; Hege S Haugnes; Sophie D Fosså; Jan Oldenburg; Lois B Travis
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

5.  Development of an ultraperformance liquid chromatography/mass spectrometry method to quantify cisplatin 1,2 intrastrand guanine-guanine adducts.

Authors:  Irene M Baskerville-Abraham; Gunnar Boysen; J Mitchell Troutman; Esra Mutlu; Leonard Collins; Kathryn E Dekrafft; Wenbin Lin; Candice King; Stephen G Chaney; James A Swenberg
Journal:  Chem Res Toxicol       Date:  2009-05       Impact factor: 3.739

Review 6.  Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.

Authors:  George D Cimino; Chong-xian Pan; Paul T Henderson
Journal:  Bioanalysis       Date:  2013-02       Impact factor: 2.681

7.  Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity.

Authors:  Jamila Laoukili; Alexander Constantinides; Emma C E Wassenaar; Sjoerd G Elias; Danielle A E Raats; Susanne J van Schelven; Jonathan van Wettum; Richard Volckmann; Jan Koster; Alwin D R Huitema; Simon W Nienhuijs; Ignace H J T de Hingh; René J Wiezer; Helma M U van Grevenstein; Inne H M Borel Rinkes; Djamila Boerma; Onno Kranenburg
Journal:  Br J Cancer       Date:  2022-02-22       Impact factor: 9.075

8.  Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance.

Authors:  John Gallon; Erick Loomis; Edward Curry; Nicholas Martin; Leigh Brody; Ian Garner; Robert Brown; James M Flanagan
Journal:  Clin Epigenetics       Date:  2021-06-05       Impact factor: 6.551

9.  Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells in vitro and in vivo.

Authors:  Ke Li; Baoan Chen; Lin Xu; Jifeng Feng; Guohua Xia; Jian Cheng; Jun Wang; Feng Gao; Xuemei Wang
Journal:  Int J Nanomedicine       Date:  2013-05-09

10.  Long-term platinum retention after treatment with cisplatin and oxaliplatin.

Authors:  Elke E M Brouwers; Alwin D R Huitema; Jos H Beijnen; Jan H M Schellens
Journal:  BMC Clin Pharmacol       Date:  2008-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.